ClinicalTrials.gg
WithdrawnNCT01386190Updated Jan 25, 2021

Impact of Exercise on Body Composition in Premature Infants

An interventional study of Exercise/Social Behavioral in Body Composition, Beneficial, sponsored by University of California, Irvine. Withdrawn at 1 site in United States. Open to participants aged 29 Weeks to 34 Weeks. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by University of California, Irvine · Not applicable, Interventional, and Prevention

Why this study was withdrawn
Non applicable clinical trial
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
29 Weeks to 34 Weeks
Sex
All
01

Study summary

This research consists of a novel intervention designed to increase physical activity of premature babies in their first year of life. The potential beneficial impact of augmented physical activity on:

  1. Body composition
  2. Associated biochemical and cellular mechanisms of growth and inflammation
  3. Quality of maternal care will be measured
Read the detailed description

Premature birth is recognized as the single most important health problem in maternal child health in the US. Paradoxically, both failure to thrive and obesity are now known to be associated with prematurity, as are osteopenia (a condition where bone mineral density is lower than normal) and increased risk of fracture, and increased risk of cardiovascular disease later in life. We lack cohesive approaches to mitigate these profound threats to health. Despite promising new research demonstrating that physical activity can stimulate the growth of muscle and bone even during intrauterine life (perhaps through metabolic programming), there have been very few attempts to implement and study physical activity interventions in the premature baby.

The challenges are substantial and include:

  • measuring body composition
  • assessing physical activity
  • engaging caregivers as partners in the intervention
  • identifying plausible and testable biological mechanisms
  • designing interventions that actually increase physical activity and match the rapid pace of motor development early in life

A developmentally dynamic physical activity intervention has been designed and pilot tested-one that engages the caregiver as a partner. Using techniques and tools as far-ranging as Dual X-ray Absorbiometry (DXA), smart phones, doubly labeled water, and lightweight, wireless accelerometers developed specifically for this purpose, the working hypothesis is that the one-year intervention will augment lean body mass (primary outcome variable) and improve bone mineralization and the ratio of lean to fat tissue (secondary outcome variables). The study will gauge the impact of the physical activity intervention on the balance between circulating anabolic mediators (insulin-like growth factor-I and growth hormone binding protein) and inflammation-associated cytokines (interleukin-6, and interleukin-1 receptor antagonist), which antagonize muscle and bone growth.

We will additionally:

  1. begin to explore how physical activity influences circulating endothelial progenitor cells, which are increasingly viewed as markers of vascular health very early in life
  2. take advantage of this prospective, interventional study to explore potential genetic determinants of growth in babies born prematurely.
  3. Finally, any study involving the premature infant and the data associated with it must be viewed in light of the critical relationship between the mother and baby.

The potential broad impact of early life interventions has been recently demonstrated by the success of the "Back-To-Sleep" campaign in mitigating sudden infant death syndrome. Should the positive effects of augmented exercise on body composition be supported, we would then anticipate widespread benefit in preventing long-term health consequences of prematurity at relatively low cost.

02

Conditions studied

  • Body Composition, Beneficial

Keywords

  • preterm infant, body composition, exercise
03

In context

Premature Birth

2,615 studies on the registry are indexed under Premature Birth; 507 are open to participants now.

Browse Premature Birth studies →

Lead sponsor

University of California, Irvine is the lead sponsor of 474 studies on the registry; 96 are open to participants now.

Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
29 Weeks to 34 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Infant Inclusion criteria:

  • Infant is a healthy, growing NICU inpatient.
  • Caregiver ≥18 years of age
  • Infant gestational age at birth \<29weeks
  • Infant gestational age at time of study recruitment >34 wks, on full feeds and nearing discharge

Infant Exclusion criteria:

  • Significant lung disease of prematurity requiring supplemental oxygen or corticosteroids at discharge
  • Significant intraventricular hemorrhage, grade III -IV
  • Necrotizing entrocolitis
  • Tracheostomy
  • Bone Diseases

    • Osteogenesis Imperfecta
    • Hip or knee joint anomalies
    • Arthrogryposis
    • Fractures
  • Skin disorders (e.g., Erythematus Bullosis)
  • Symptomatic congestive heart disease
  • Any other conditions or congenital anomalies likely to severely impact the ability of the premature baby and caregiver to participate in a demanding study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Exercise Group

    Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.

    Other: Exercise/Social Behavioral

  • Active comparator
    Control

    Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.

    Other: Exercise/Social Behavioral

Interventions

  • OtherExercise/Social Behavioral

    Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.

06

What researchers measure

Primary outcomes

  1. Change in Lean Body Mass (LBM) as assessed by Dual X-ray Absorbiometry(DXA) at age 34-40 weeks gestational age and 86-92 weeks of age

    LBM (lean body mass) will be measured and compared at the UCI Institute for Clinical and Translational Science. Dual X-ray Absorbiometry (DXA) scan to measure lean mass will be done using a whole body fan-beam scanner (Hologic QDR Discovery-A Hologic Inc., Bedford MA)at age 34-40 weeks gestational age and again at 86-92 weeks of age

    Time frame: ages: 34-40 weeks gestational age and 86 - 92 weeks of age

Secondary outcomes

  1. Blood sample

    Blood sample (IGF-I)insulin-like growth factor-I , (GHBP)growth hormone binding protein, (IL-1ra)interleukin-1 receptor antagonist,(IL-6)interleukin-6, (EPCs)Epithelial Progenitor Cells. Inflammatory/Stress and growth factors will be measured from infant blood. A blood sample will be obtained from the NICU before discharge. A second blood sample will be obtained (venous) from the infant at 1 year.The Enzyme-linked immunosorbent assay (ELISAs) for IGF-I, IL-6, GHBP, and IL-1ra are available and routinely performed in our laboratory.

    Time frame: ages: 34-40 weeks gestational age and 86 - 92 weeks of age

  2. Energy Expenditure 1 Accelerometer three time points in the study

    Accelerometers provide robust, high fidelity logging of observed limb acceleration. The devices are worn in a canonical and identical orientation relative to the anatomy of each infant. Sleep/wake cycles of the babies will be synchronized to assure that comparable activity.

    Time frame: ages: 34-40 weeks gestational age, 52-68 weeks and 86 - 92 weeks of age

  3. Energy expenditure 2 Total Energy Expenditure as assessed by Doubly Labeled Water

    A study a subset of 100 of our enrollees will have total energy expenditure assessed by DLW. DLW measurements in children will be sent to our subcontract William Wong at Baylor University

    Time frame: age: 86-92 weeks

  4. Diet Assessments

    Parents will be called at two random days during the week of the assessment, thereby making sure that the recall interviews capture 1 weekday and 1 weekend day. Information on infant nutrition will also be obtained by three 24-h dietary recall interviews with the primary caregiver. Each interview will take approximately 20-30 minutes.

    Time frame: ages: 34-40 weeks gestational age, 52-68 weeks and 86 - 92 weeks of age

  5. Quality of Caregiver-Child Interaction

    A standardized laboratory protocol developed for the National Institute of Child Health and Human Development (NICHD) Study of Early Child Care and Youth Development and used currently by our group of researchers will be administered to determine quality of maternal infant interaction. For this protocol, observations are made during semi-structured play.

    Time frame: ages: 34-40 weeks gestational age and 86 to 92 weeks of age

  6. TIMP/AIMS

    TIMP(Test of Infant Motor Performance)/AIMS(Alberta Infant Motor Scale) The AIMS (Alberta Infant Motor Scale) is a reliable norm-referenced observational motor assessment. The AIMS measures qualitative aspects of movement and it is sensitive to changes in infant's motor performance. We also plan a test of motor development (TIMP, Test of Infant Motor Performance) that was developed specifically for newborns, overlaps well with the AIMS, and can be used to guide our exercise intervention in the first months of life.

    Time frame: ages: 34-40 weeks gestational age and 86 to 92 weeks of age

07

Study locations

1 site
  • University of California, Irvine Douglas Hospital
    Orange, California 92868, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2011
First posted
Jun 30, 2011
Start
Jun 2011
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01386190
Responsible party
Sponsor
First posted
Jun 30, 2011
Start date
Jun 2011
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Jan 25, 2021

Study contacts

Dan M. Cooper, MD
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion